Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Submitted by
admin
on February 20, 2013 - 5:12pm
Source:
Yahoo
News Tags:
Bayer
Eyelea
Regeneron
Russia
Asia
DME
diabetic macular edema
Headline:
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Do Not Allow Advertisers to Use My Personal information
